Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase Safe Implementation of Treatments in Stroke (SITS) Symptomatic Intracerebral Hemorrhage Risk Score

被引:326
作者
Mazya, Michael [1 ]
Egido, Jose A. [2 ]
Ford, Gary A. [3 ]
Lees, Kennedy R. [4 ,5 ]
Mikulik, Robert [6 ]
Toni, Danilo [7 ]
Wahlgren, Nils [1 ]
Ahmed, Niaz [1 ]
机构
[1] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden
[2] Univ Complutense Madrid, Hosp Clin San Carlos, Stroke Unit, E-28040 Madrid, Spain
[3] Newcastle Univ, Inst Ageing & Hlth, Stroke Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[4] Univ Glasgow, Inst Cardiovasc & Med Sci, Acute Stroke Unit, Glasgow, Lanark, Scotland
[5] Univ Glasgow, Cerebrovasc Clin, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[6] St Annes Hosp, Dept Neurol, Int Clin Res Ctr, Brno, Czech Republic
[7] Univ Roma La Sapienza, Dept Neurol & Psychiat, Rome, Italy
关键词
cerebral infarct; database; intracerebral hemorrhage; prognosis; stroke management; thrombolysis; TISSUE-PLASMINOGEN ACTIVATOR; COOPERATIVE ACUTE STROKE; THROMBOLYTIC THERAPY; DOUBLE-BLIND; TRANSFORMATION; TRIAL;
D O I
10.1161/STROKEAHA.111.644815
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Symptomatic intracerebral hemorrhage (SICH) is a serious complication in patients with acute ischemic stroke treated with intravenous thrombolysis. We aimed to develop a clinical score that can easily be applied to predict the risk of SICH. Methods-We analyzed data from 31 627 patients treated with intravenous alteplase enrolled in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register. The outcome measure was SICH per the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) definition: a Type 2 parenchymal hemorrhage with deterioration in National Institutes of Health Stroke Scale score of >= 4 points or death. Univariate risk factors associated with the outcome were entered into a logistic regression model after stratification of continuous variables. Adjusted ORs for the independent risk factors were converted into points, which were summated to produce a risk score. Results-We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension. The overall rate of SICH was 1.8%. The risk score ranged from 0 to 12 points and showed a >70-fold graded increase in the rate of SICH for patients with a score >= 10 points (14.3%) compared with a score of 0 point (0.2%). The prognostic discriminating capability by C statistic was 0.70. Conclusions-The SITS SICH risk score predicts large cerebral parenchymal hemorrhages associated with severe clinical deterioration. The score could aid clinicians to identify patients at high as well as low risk of SICH after intravenous alteplase. (Stroke. 2012; 43: 1524-1531.)
引用
收藏
页码:1524 / 1531
页数:8
相关论文
共 33 条
  • [11] Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic Stroke Pooled Analysis of Placebo Data From the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials
    Cucchiara, Brett
    Kasner, Scott E.
    Tanne, David
    Levine, Steven R.
    Demchuk, Andrew
    Messe, Steven R.
    Sansing, Lauren
    Lees, Kennedy R.
    Lyden, Patrick
    [J]. STROKE, 2009, 40 (09) : 3067 - 3072
  • [12] Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
    Davis, Stephen M.
    Donnan, Geoffrey A.
    Parsons, Mark W.
    Levi, Christopher
    Butcher, Kenneth S.
    Peeters, Andre
    Barber, P. Alan
    Bladin, Christopher
    De Silva, Deidre A.
    Byrnes, Graham
    Chalk, Jonathan B.
    Fink, John N.
    Kimber, Thomas E.
    Schultz, David
    Hand, Peter J.
    Frayne, Judith
    Hankey, Graeme
    Muir, Keith
    Gerraty, Richard
    Tress, Brian M.
    Desmond, Patricia M.
    [J]. LANCET NEUROLOGY, 2008, 7 (04) : 299 - 309
  • [13] Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator A Science Advisory From the American Heart Association/American Stroke Association
    del Zoppo, Gregory J.
    Saver, Jeffrey L.
    Jauch, Edward C.
    Adams, Harold P., Jr.
    [J]. STROKE, 2009, 40 (08) : 2945 - 2948
  • [14] Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update
    Derex, L.
    Nighoghossian, N.
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (10) : 1093 - 1099
  • [15] Is the Maximum Dose of 90 mg Alteplase Sufficient for Patients With Ischemic Stroke Weighing >100 kg?
    Diedler, Jennifer
    Ahmed, Niaz
    Glahn, Joerg
    Grond, Martin
    Lorenzano, Svetlana
    Brozman, Miroslav
    Sykora, Marek
    Ringleb, Peter
    [J]. STROKE, 2011, 42 (06) : 1615 - 1620
  • [16] Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy at Stroke Onset
    Diedler, Jennifer
    Ahmed, Niaz
    Sykora, Marek
    Uyttenboogaart, Maarten
    Overgaard, Karsten
    Luijckx, Gert-Jan
    Soinne, Lauri
    Ford, Gary A.
    Lees, Kennedy R.
    Wahlgren, Nils
    Ringleb, Peter
    [J]. STROKE, 2010, 41 (02) : 288 - 294
  • [17] Hemorrhagic transformation within 36 hours of a cerebral infarct - Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort
    Fiorelli, M
    Bastianello, S
    von Kummer, R
    del Zoppo, GJ
    Larrue, V
    Lesaffre, E
    Ringleb, AP
    Lorenzano, S
    Manelfe, C
    Bozzao, L
    [J]. STROKE, 1999, 30 (11) : 2280 - 2284
  • [18] Intravenous Alteplase for Stroke in Those Older Than 80 Years Old
    Ford, Gary A.
    Ahmed, Niaz
    Azevedo, Elsa
    Grond, Martin
    Larrue, Vincent
    Lindsberg, Perttu J.
    Toni, Danilo
    Wahlgren, Nils
    [J]. STROKE, 2010, 41 (11) : 2568 - 2574
  • [19] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [20] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017